New Drug Targets Bone Disease That Causes Hearing Loss
The drug LGK974, which inhibits the Wnt signaling pathway, shows promise in reversing excessive bone growth in sclerosteosis.
The drug LGK974, which inhibits the Wnt signaling pathway, shows promise in reversing excessive bone growth in sclerosteosis.
The VisualEyes VNG update features new, data-driven assessments to help clinicians understand how patients function in daily activities.
HCPs can expand their impact by increasing awareness of the diverse causes of hearing loss and by actively connecting with both current and potential patients through community outreach and professional partnerships.
The newly released Counseling-Infused Audiologic Care offers a practical, person-centered guide to audiologic counseling rooted in evidence-based practice.
Researchers have identified and mapped diverse cell types in the cochlear nucleus, a critical part of the auditory system, advancing understanding of how our brains process sounds and paving the way for targeted treatments for auditory disorders.
Lenire is sponsoring the 10th Annual Hearoes Tour to expand access to hearing and tinnitus care for U.S. veterans through free nationwide screenings and support.
A NIOSH study highlights that construction workers face higher risks of hearing loss due to hazardous noise and chemicals, identifying key sub-sectors most affected and recommending strategies to reduce exposure.
Starkey’s AI-powered Balance Assessment feature, which uses motion sensors in hearing aids to assess fall risk, offers a new tool for proactive health monitoring.
Henry Schein is donating essential healthcare products to be used for athlete health screenings at the 2025 Special Olympics World Winter Games in Turin, Italy.